RxDoctor Payments Data

Abhishek Anand, MD

Neurology · Oxon Hill, MDNPI 1881038750

Payments from drug & device makers

$1,411in general payments, 2019–2025

Across 47 payments — averaging $30.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$680
  • Novo Nordisk$122
  • UCB, Inc.$118
  • Lundbeck LLC$97
  • EMD Serono, Inc.$91
  • Amgen$63
  • plus $239 from 9 others

What the payments were for

  • Food & beverage$1,411100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,411 in reported general payments places this provider in the 40th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$217,966
Medicare patients
817
Services billed
1,435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa27$24,038
RexultiBrexpiprazole11$18,369
FycompaPerampanel13$15,489
Memantine Hcl333$12,975
Rivastigmine57$11,756
Levetiracetam223$7,395
Donepezil Hcl347$3,324
Memantine Hcl ErMemantine Hcl15$3,049
Carbidopa-LevodopaCarbidopa/Levodopa111$2,551
Lacosamide37$2,248
Propranolol Hcl ErPropranolol Hcl67$2,197
AmantadineAmantadine Hcl22$1,647
Duloxetine Hcl97$1,168
Lidocaine25$1,048
RivastigmineRivastigmine Tartrate24$1,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$32$24,03827 claims
Otsuka America Pharmaceutical, Inc.Rexulti$15$18,36911 claims
Eisai Inc.Fycompa$56$15,48913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 442 neurology providers in Maryland.

Other neurology in Oxon Hill

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →